ARGONAUT II Study of the <i>In Vitro</i> Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae
Michael R. Jacobs, Caryn E. Good, Andrea M. Hujer, Ayman M. Abdelhamed, Daniel D. Rhoads, Kristine M. Hujer, Susan D. Rudin, Tatiana Domitrovic, Lynn Connolly, Kevin M. Krause, Robin Patel, César A. Arias, Barry N. Kreiswirth, Laura J. Rojas, Roshan D’Souza, Richard C. White, Lauren Brinkac, Kevin Nguyen, Indresh Singh, Derrick E. Fouts, David van Duin, Robert A. Bonomo, for the Antibacterial Resistance Leadership Group
Abstract
Plazomicin was tested against 697 recently acquired carbapenem-resistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC 50 and MIC 90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of >32 mg/liter). Resistance was associated with rmtF -, rmtB -, or armA -encoded 16S rRNA methyltransferases in all except 1 isolate.